Celltrion’s Bone Disease Biosimilar Wins FDA Approval in the U.S.
Celltrion announced on the 4th that its bone disease treatment biosimilars Stoboclo and Osenvelt—biosimilars of Prolia and Xgeva…
Xgeva
1 개의 기사가 있습니다.